Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
An association of a polysaccharide (glucomannan) obtained from Candida utilis and a protein rich in glutamine obtained from ungerminated seeds of Ricinus communis on an inorganic matrix of calcium sulphate and phosphate.
Oral administration 3 times a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its high molecular weight makes transfer into breastmilk in significant quantities unlikely.
Due to its protein and glucidic nature it is digested in the intestine, so it has a low oral bioavailability (CECMED 2015), which hinders passage to infant plasma from breastmilk.
It has no side effects.
Its efficacy as an immunomodulator is not proven (Murciasalud 2006).
The literature on this drug is scarce and/or out-of-date, and it is sold in few countries.
It has zero or low therapeutic utility, and is totally non-essential.